
Tagomics is a UK-based company developing a proprietary multiomic platform that integrates genetic, epigenetic, and fragmentomic features to unlock disease-associated biomarkers from various biological sources. Their technology combines advanced bioinformatics and machine learning to provide unique biological insights, enabling high-throughput, economical, and automatable multiomic disease profiling. Tagomics focuses on transforming disease diagnosis, particularly in oncology and other clinical applications, by offering enhanced sensitivity, specificity, and deeper clinical insights. The company collaborates with biopharma and clinical research institutions to develop genomics-based diagnostics and precision medicines, with notable partnerships such as a co-marketing agreement with Agilent Technologies. They have received significant funding, including a £860k Innovate UK Biomedical Catalyst grant for colorectal cancer detection, and have raised £6.7m in funding rounds, positioning them as an innovative player in the genomics and diagnostics market.

Tagomics is a UK-based company developing a proprietary multiomic platform that integrates genetic, epigenetic, and fragmentomic features to unlock disease-associated biomarkers from various biological sources. Their technology combines advanced bioinformatics and machine learning to provide unique biological insights, enabling high-throughput, economical, and automatable multiomic disease profiling. Tagomics focuses on transforming disease diagnosis, particularly in oncology and other clinical applications, by offering enhanced sensitivity, specificity, and deeper clinical insights. The company collaborates with biopharma and clinical research institutions to develop genomics-based diagnostics and precision medicines, with notable partnerships such as a co-marketing agreement with Agilent Technologies. They have received significant funding, including a £860k Innovate UK Biomedical Catalyst grant for colorectal cancer detection, and have raised £6.7m in funding rounds, positioning them as an innovative player in the genomics and diagnostics market.
Location: Cambridge, United Kingdom
Founded: 2020
Core tech: Proprietary multiomic/epigenomic platform (Interlace; Activace/Active-Seq)
Recent funding: £860k Innovate UK grant (Jun 10, 2025); £6.7M Seed (Feb 21, 2024)
Focus: Disease biomarker discovery and diagnostics (oncology; early colorectal cancer)
Early disease detection and biomarker discovery for diagnostics and precision medicine, with applications in oncology (including early colorectal cancer).
2020
Biotechnology
£6.7M
Participating investors included Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures, OMX Ventures, Meltwind Advisory, and MEIF-related funds
£860k
Innovate UK Biomedical Catalyst grant to develop early colorectal cancer detection test and run a 250-patient pilot
“Calculus Capital, Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures, OMX Ventures, Meltwind Advisory, Innovate UK”
| Company |
|---|
Permanent - Full time - Hybrid (Cambridge)
About Tagomics Tagomics is a Cambridge-based biotechnology company developing a next-generation multi-omic biomarker discovery platform to transform how disease and organ health are understood, measured, and monitored.
Originating from pioneering research by Dr Robert Neely and colleagues at the University of Birmingham, our proprietary technology integrates genetic, epigenetic, and fragmentomic features from circulating cell-free DNA. Combined with advanced bioinformatics and machine-learning approaches, this enables deep biological insight across applications ranging from early cancer detection to drug safety and organ health monitoring.
Learn more about our technology from our recent scientific paper - http://tinyurl.com/TagomicsPaper
As we move towards the launch of our first commercial products, Tagomics is entering an exciting phase of growth. We are expanding our multidisciplinary team and relocating to new laboratories and offices at Babraham Research Campus, one of Europe’s leading life-science hubs.
Joining Tagomics means contributing to a scientifically rigorous, collaborative environment where your work will directly shape a unique technology that will transform our understanding of disease and diagnosis.
About The Role You will play a key role in analysing sequencing and epigenetic datasets that drive Tagomics’ biomarker discovery programmes. Working at the interface of research and product development, you will apply bioinformatics methods to both exploratory R&D questions and the generation of robust, reusable analyses that support our evolving product pipeline.
Combining pipelines and cloud-based infrastructure, you will help turn complex multi-omic data into biological insights. This role is ideal for recent PhD graduates or early-career scientists seeking hands-on experience in applied bioinformatics within a fast-growing company. You will be supported through mentorship and training, while progressively taking greater ownership of analyses and contributing to projects with direct scientific and commercial impact.
Key Responsibilities
Essential Requirements
Desirable Requirements
Skills and Competencies
Approach to work: what we value
Hiring Process
Our Hiring Process Consists Of 3 Main Stages 1 - Screening Call – A conversation to discuss your relevant experience, career goals, and answer your questions about the role and company
2 – Technical Interview – A live online session assessing your technical abilities, including subject-matter questions and a short presentation on a take-home bioinformatics challenge.
3 - Team Interview – Meet with leadership and your future teammates to discuss collaboration, team dynamics, and how you'll contribute to our projects
Why join Tagomics?
Tagomics is a small but rapidly growing company. Joining us at this stage offers the opportunity to gain broad exposure to multiple aspects of start-up life, contribute meaningfully to our technology, and help shape our culture as we grow.
We believe in flexible working and in maintaining a sustainable work–life balance. This role is hybrid, with a minimum of two days per week in the office.
What We Offer
Our offices at Babraham Research Campus are modern, lift-accessible, and well connected, with on-site parking, bike facilities, and public transport links (Cambridge–Linton–Haverhill bus route). The campus also offers a gym, restaurant, and nearby countryside Pub.
Please note: we are not currently able to sponsor visas for this role. Applicants must have the right to work in the UK.